-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KD1oYUMDws2Ik40xOV2z2j43urQf+ZMJWdpSlnUw8BFo5GkGAn7fKDZyZmB1uYPt
 kBLlmXUT3IPU6dEGP9DwFg==

<SEC-DOCUMENT>0001354457-09-000192.txt : 20090710
<SEC-HEADER>0001354457-09-000192.hdr.sgml : 20090710
<ACCEPTANCE-DATETIME>20090710095234
ACCESSION NUMBER:		0001354457-09-000192
CONFORMED SUBMISSION TYPE:	25-NSE
CONFIRMING COPY:	
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090710
DATE AS OF CHANGE:		20090710

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		25-NSE
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NASDAQ Stock Market LLC
		CENTRAL INDEX KEY:			0001354457
		IRS NUMBER:				521165937
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		25-NSE

	BUSINESS ADDRESS:	
		STREET 1:		9600 BLACKWELL RD
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-978-4144

	MAIL ADDRESS:	
		STREET 1:		9600 BLACKWELL RD
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>25-NSE
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<notificationOfRemoval>

    <schemaVersion>X0203</schemaVersion>

    <exchange>
        <cik>0001354457</cik>
        <entityName>NASDAQ Stock Market LLC</entityName>
    </exchange>

    <issuer>
        <cik>0001023549</cik>
        <entityName>XTL BIOPHARMACEUTICALS LTD</entityName>
        <fileNumber>000-51310</fileNumber>
        <address>
            <street1>711 Executive Boulevard, Suite Q</street1>
            <street2></street2>
            <city>New York</city>
            <stateOrCountryCode>NY</stateOrCountryCode>
            <stateOrCountry>NEW YORK</stateOrCountry>
            <zipCode>10989</zipCode>
        </address>
        <telephoneNumber>845-267-0707</telephoneNumber>
    </issuer>

    <descriptionClassSecurity>American Depositary Receipts</descriptionClassSecurity>

    <ruleProvision>17 CFR 240.12d2-2(b)</ruleProvision>

    <signatureData>
        <signatureName>Amy Horton</signatureName>
        <signatureTitle>Associate General Counsel</signatureTitle>
        <signatureDate>2009-07-10</signatureDate>
    </signatureData>
</notificationOfRemoval>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.25
<SEQUENCE>2
<FILENAME>xtlbdelistreason.txt
<TEXT>
Delisting Determination,The Nasdaq Stock Market, LLC,
July 10, 2009, XTL Biopharmaceuticals Ltd. The Nasdaq Stock
Market, Inc. (the Exchange) has determined to remove from
listing the common stock of XTL Biopharmaceuticals Ltd.
(the Company), effective at the opening of the
trading session on July 20, 2009. Based on a review of
the information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for
listing on the Exchange pursuant to Listing Rules
5100 and 5550(b)(1). The Company was notified of the
Staffs determination on January 27, 2009. The Company
requested a review of the Staffs determination before the
Listing Qualifications Hearings Panel. Upon review of the
information provided by the Company, the Panel determined
that the Company did not qualify for inclusion on the
Exchange based on its failure to comply with the following
Listing Rules: 5100 and 5550(b)(1). The Company was notified
of the Panels decision on April 15, 2009 and
trading in the Companys securities was suspended on
April 17, 2009. The Company did not request a review
of the Panels decision by the Nasdaq Listing and Hearing
Review Council. The Listing Council did not call the
matter for review. The Panels Determination to delist
the Company became final on June 1, 2009.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
